Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH)

[1]  G. Emons,et al.  Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. , 2011, Oncology reports.

[2]  H. Sindermann,et al.  Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. , 2010, Gynecologic oncology.

[3]  M. Beckmann,et al.  378 Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer. Protocol AGO-GYN 5, AGO Study Group, Germany , 2010 .

[4]  J. Sehouli,et al.  Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer. , 2010 .

[5]  A. Schally,et al.  Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition. , 2009, International journal of oncology.

[6]  H. Sindermann,et al.  Luteinizing Hormone-Releasing Hormone Receptor-Targeted Chemotherapy Using AN-152 , 2009, Neuroendocrinology.

[7]  U. Kompella,et al.  Luteinizing hormone-releasing hormone receptor–targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy , 2009, Molecular Cancer Therapeutics.

[8]  A. Schally,et al.  Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. , 2007, Molecular pharmaceutics.

[9]  A. Schally,et al.  Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[10]  A. Schally,et al.  525 POSTER Targeting Doxorubicin to LHRH-receptor positive tumors by the cytotoxic hybrid ZEN-008 (AN-152) , 2006 .

[11]  A. Schally,et al.  Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations , 2006, Proceedings of the National Academy of Sciences.

[12]  A. Schally,et al.  Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207. , 2005, Fertility and sterility.

[13]  T. Schlott,et al.  Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. , 2004, American journal of obstetrics and gynecology.

[14]  A. Schally,et al.  Chemotherapy targeted to cancers through tumoral hormone receptors , 2004, Trends in Endocrinology & Metabolism.

[15]  A. Bajo,et al.  Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  A. Schally,et al.  New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. , 2003, Life sciences.

[17]  A. Schally,et al.  Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. , 2002, American journal of obstetrics and gynecology.

[18]  G. Emons,et al.  Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. , 2002, American journal of obstetrics and gynecology.

[19]  A. Schally,et al.  Hypothalamic Hormones and Cancer , 2001, Frontiers in Neuroendocrinology.

[20]  A. Bajo,et al.  Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness. , 2001, International journal of oncology.

[21]  A. Schally,et al.  Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. , 2000, International journal of oncology.

[22]  A. Schally,et al.  Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice , 2000, Breast Cancer Research and Treatment.

[23]  A. Schally,et al.  Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. , 1999, Cancer letters.

[24]  E. Jenison,et al.  Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. , 1998, International journal of oncology.

[25]  A. Schally,et al.  Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. , 1997, Journal of the National Cancer Institute.

[26]  M Kovacs,et al.  Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Schally,et al.  High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. , 1993, The Journal of clinical endocrinology and metabolism.

[28]  A. Schally,et al.  High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. , 1993, Cancer research.

[29]  A. Schally,et al.  Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. , 1990, Cancer research.

[30]  G. Emons,et al.  Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. , 1989, European journal of cancer & clinical oncology.

[31]  A. Schally,et al.  Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. , 2011, Current drug delivery.

[32]  A. Schally,et al.  Characteristics and distribution of receptors for [d‐trp6]‐ luteinizing hormone‐releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer , 1989, Journal of clinical laboratory analysis.